AREG and colorectal carcinoma: Several clinical studies have found that low expression levels of AREG and EREG are related to the low response rate to cetuximab in KRAS-WT CRC patients, but not in CRC patients with KRAS-mutation (Khambata-Ford et al., 2007; Jacobs et al., 2009).